文献速递前列腺癌

PSMA-PET在前列腺癌局灶治疗规划与随访中是否有作用

Is there a role of PSMA-PET in focal therapy planning and follow-up?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-02-13

本系统综述检索PubMed和Scopus数据库,纳入7项报告前列腺癌局灶治疗前后PSMA-PET数据的研究(2项病例报告、1项回顾性研究、4项前瞻性单中心研究),采用叙述性综合总结。PSMA-PET在术前规划与分期、活检引导与感兴趣区定义、随访成像方面显示有前景但尚未验证的结果,证据有限且不确凿。

要点

  • 纳入7项研究:2项病例报告、1项回顾性研究、4项前瞻性单中心研究,偏倚风险为中重度。
  • PSMA-PET可能辅助多参数MRI用于局灶治疗术前规划与随访,但结果尚未验证。
  • 证据有限且不确凿,PSMA-PET在局灶治疗领域的应用仍存争议。

核心结论

  • 关于PSMA-PET在局灶治疗术前评估、治疗引导及作为评估治疗成败与随访的无创工具方面,现有证据有限。
  • 尽管当前证据仍有限且不确凿,PSMA-PET显示出有前景的结果并具有多种可能的应用。

研究设计与样本

  • 系统综述,文献检索使用PubMed和Scopus数据库,遵循PRISMA声明推荐。
  • 纳入所有报告前列腺癌局灶治疗前和/或后行PSMA-PET数据的研究。
  • 共纳入7项研究:2项病例报告、1项回顾性研究、4项前瞻性单中心研究。
  • 采用叙述性综合总结综述发现,因研究异质性和局限性未进行定量合成。
  • 纳入研究的偏倚风险评估为中重度。

主要发现

  • PSMA-PET在局灶治疗领域显示出有前景但尚未验证的结果,具有多种可能的应用。
  • 应用包括:术前规划与分期,旨在通过识别前列腺内可疑病灶及更准确的局部和全身分期来改善患者选择。
  • 应用包括:引导活检和感兴趣区定义。
  • 应用包括:作为随访成像工具,旨在减少不必要的监测活检次数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因研究的异质性和局限性未进行定量合成。
  • 纳入研究的偏倚风险评估为中重度。
  • 关于PSMA-PET在局灶治疗领域的证据有限。
  • 当前证据仍有限且不确凿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Focal therapy (FT) is a promising alternative to radical treatments for localized Prostate Cancer (PCa) in selected patients. However, it is not yet considered a standard treatment option, and there is currently no consensus on managing patients after FT. In this context, Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) may support multiparametric MRI (mpMRI) for both pre-operative planning and follow-up. The aim of this systematic review was to provide a comprehensive overview of the current applications of PSMA-PET in the field of FT and to analyze its future perspectives. EVIDENCE ACQUISITION: A literature search was performed using PubMed and Scopus databases, following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement recommendations. All studies reporting data on PSMA-PET performed before and/or after FT for PCa were included. A narrative synthesis was employed to summarize the review findings. No quantitative synthesis was performed due to the heterogeneity and limitations of the studies. EVIDENCE SYNTHESIS: Seven studies (2 case reports, 1 retrospective, and 4 prospective single-center studies) were included in this review. A moderate-severe risk of bias was assessed for the included studies. In the field of FT, PSMA-PET showed promising but yet not validated results with several possible applications: (1) pre-operative planning and staging, aiming to improve patient selection trough the identification of intraprostatic suspected lesions and more accurate local and systemic staging; (2) guidance for biopsy and Region of Interest (ROI) definition; (3) follow-up imaging tool, aiming to decrease the number of unnecessary surveillance biopsies. CONCLUSIONS: Limited evidence exists regarding the use of PSMA-PET in the field of FT, considering pre-operative setting, treatment guidance and its use as a non-invasive tool to evaluate treatment success or failure and for follow-up. In this scenario, even if the current evidence is still limited and inconclusive, PSMA-PET showed promising results with several possible applications.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Nicoletti R, Alberti A, Gauhar V, et al. Is there a role of PSMA-PET in focal therapy planning and follow-up? Prostate Cancer Prostatic Dis. 2025. PMID: 39939364. doi:10.1038/s41391-025-00944-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。